Liver Transplantation for HBV ‐Related Disease in France: NUC Type Before LT Is Associated With Patient Survival

@article{bienvenue2026liver,
  title = {{Liver Transplantation for HBV ‐Related Disease in France: NUC Type Before LT Is Associated With Patient Survival}},
  author = {Isaure Bienvenue and Olivier Roux and Audrey Coilly and Armand Abergel and Teresa Antonini and Thierry Artzner and Olivier Boillot and Faïza Chermak and Filomena Conti and Sébastien Dharancy and Christophe Duvoux and Laure Elkrief and Marwin Farrugia and Claire Francoz and Baptiste Giguet and Jean Hardwigsen and Pauline Houssel‐debry and Marie-Noelle Hilleret and Nassim Kamar and Marianne Latournerie and Magdalena Meszaros and Sylvie Radenne and Bruno Roche and Ephrem Salamé and Delphine Verhoeven Weil and Didier Samuel and Fabien Zoulim and Jérôme Dumortier and François Villeret},
  journal = {Liver -Copenhagen-},
  year = {2026},
  month = nov,
  doi = {10.1111/liv.70737},
  url = {https://hal.science/hal-05851707v1},
  note = {CC BY 4.0},
}

TY  - JOUR
TI  - Liver Transplantation for HBV ‐Related Disease in France: NUC Type Before LT Is Associated With Patient Survival
AU  - Isaure Bienvenue
AU  - Olivier Roux
AU  - Audrey Coilly
AU  - Armand Abergel
AU  - Teresa Antonini
AU  - Thierry Artzner
AU  - Olivier Boillot
AU  - Faïza Chermak
AU  - Filomena Conti
AU  - Sébastien Dharancy
AU  - Christophe Duvoux
AU  - Laure Elkrief
AU  - Marwin Farrugia
AU  - Claire Francoz
AU  - Baptiste Giguet
AU  - Jean Hardwigsen
AU  - Pauline Houssel‐debry
AU  - Marie-Noelle Hilleret
AU  - Nassim Kamar
AU  - Marianne Latournerie
AU  - Magdalena Meszaros
AU  - Sylvie Radenne
AU  - Bruno Roche
AU  - Ephrem Salamé
AU  - Delphine Verhoeven Weil
AU  - Didier Samuel
AU  - Fabien Zoulim
AU  - Jérôme Dumortier
AU  - François Villeret
PY  - 2026
DA  - 2026/11/04
JO  - Liver -Copenhagen-
DO  - 10.1111/liv.70737
UR  - https://hal.science/hal-05851707v1
AB  - Background & aims: Liver transplantation (LT) is indicated for liver complications related to hepatitis B virus (HBV) infection: acute liver failure (ALF), decompensated cirrhosis or hepatocellular carcinoma (HCC). The present study aimed to describe and evaluate patient survival after LT for HBV-related disease in France and identify the factors influencing survival. Methods: The present retrospective cohort study based on medical record information included all adult patients transplanted with positive HBsAg (+/- coinfection with Hepatitis D virus (HDV)) between January 1, 2005 and December 31, 2023 in all French LT centres. Results: The study population consisted of 1083 patients, the majority of whom were men (81.5%) with a median [IQR] age at LT listing of 52.8 [42.5-59.8] years. Indications for LT were HBV-related HCC (47.2%), HBV-related cirrhosis (28.5%), HDV-related cirrhosis (11.2%), HBV-related ALF (10.5%), HDV-related HCC (1.4%) and other (0.7%). Median [IQR] post-LT follow-up was 6.0 [2.2-11.1] years. Patient survival at 1, 5, 10 and 15 years after LT was 91.6%, 80.1%, 71.8% and 63.6% respectively. Multivariate analysis showed that independent significant prognostic factors were age at LT (HR: 1.030; 95CI: 1.019-1.042; p < 0.0001) and the pre-LT nucleos(t)ides analogue (NUC) regimen: in comparison to tenofovir, the use of entecavir alone (HR: 1.735; 95CI: 1.312-2.295; p < 0.0001) or another NUC or combination therapy (HR: 1.471; 95CI: 1.059-2.043; p = 0.021) were associated with decreased survival. Conclusions: Survival after LT for HBV-related liver disease is good. NUC type prior to LT seems to be associated with patient survival.
SN  - 0106-9543
SN  - 1600-0676
ER  -